

Author Year; Country Score Research Design Total Sample Size	Methods	Outcome
Invernizzi et. al 2015 Italy Case-Control Study Level 3 N=43	<p>Population: 28 participants (23 men, 5 women) with chronic SCI; AIS A-C; C5 – T12; age: 40.5 ± 7.1 years; TPI: 90.8 ± 53.1 months; 24 paraplegic, 4 tetraplegic, 22 motor complete and 6 motor incomplete SCI individuals. 15 healthy controls (5 men, 10 women; age: 28.4 ± 4.1 years).</p> <p>Outcome Measures: Serum sclerostin was measured by SOST Elisa Kit (Biomedica Gruppe, Vienna, Austria), myostatin quantified by the Elisa assay (MyBioSource, San Diego, CA, USA)</p>	<ol style="list-style-type: none"> 1. Sclerostin Range of values [mean ± SD] SCI: 70 ± 30 pmol/l Controls: 25 ± 5 pmol/l Normal value: 0 - 240 pmol/l MCID/LSC: - Important association: serum sclerostin levels were statistically higher in individuals suffering from SCI compared with healthy controls 2. Myostatin Range of values [mean±SD] SCI: 17 ± 6 ng/ml Controls: 7 ± 6 ng/ml Normal range: 0.625 – 20 ng/ml MCID/LSC: - Important association: myostatin serum levels are significantly higher in individuals with SCI than those in healthy controls; strong correlation with appendicular muscle mass index and moderate correlation with serum sclerostin in motor complete SCI

* All data expressed as mean±SD, unless expressed otherwise.